Redx Pharma's (LON:REDX) Lisa Anson presents the company's 'key progresses' made during their full year results for 2020.
Anson marks a transformational year for the company with significant pipeline progression and further development of lead programmes in oncology and fibrosis.
She takes investors through, step by step, beginning with progress made on the Phase 1/2a trial of their lead oncology asset, RXC004, a potentially best-in-class, orally bioavailable, porcupine inhibitor. And RXC007 is expected to enter a Phase 1 study in H1 2021.
The company has also announced the appointment of Dr Jane Robertson as Chief Medical Officer as well as significant deals made with AstraZeneca.
